Am J Health Syst Pharm. 2008;65(12):1180-1183. Ultimately, more formalized, high-quality, and clinically applicable studies are necessary to determine the safety of the parenteral combination of ...
Schizophrenia and bipolar I disorder are two conditions that have many differences between them. A class of medicines called antipsychotics can be used to treat both conditions but may cause unwanted ...
Clinical trial data support the NDA for TEV-'749, demonstrating that once-monthly olanzapine improves symptoms in patients with schizophrenia. The Food and Drug Administration (FDA) has accepted for ...
Yoga-based supportive care for patients with head and neck cancer undergoing radiotherapy: Results of a three-arm randomized controlled trial. This is an ASCO Meeting Abstract from the 2023 ASCO ...
PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), ...
The population-based cohort study included electronic health record data from the Hong Kong Hospital Authority for more than 11,051 adults with schizophrenia. Participants had used clozapine (n = 1450 ...
Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), together with Medincell, announced that the U.S. Food and Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results